Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

BHB-Phe, a newly discovered compound, reduces appetite and body weight by activating specific brain neurons. Researchers from ...

Scientists have confirmed the cannabis ingredient cannabinol (CBN) can increase sleep in rats, highlighting a new path for ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist, a highly potent, peripherally restricted new chemical entity, ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...